Reduced pretomanid exposures.
Avoid coadministration with strong or moderate CYP3A inducers.
Source: G&G 14e · p1277
Bicyclic nitroimidazole · Antituberculosis
Pretomanid inhibits M. tuberculosis mycolic acid and protein synthesis under aerobic conditions. It is a prodrug requiring bacterial activation via a nitroreduction step involving FGD1 (NADP-dependent G6PD) and cofactor F420. In nonreplicating persistent bacilli, it generates reactive nitrogen species such as nitric oxide via its des-nitro metabolite, augmenting the kill of intracellular NRPB, and causes ATP depletion by poisoning the respiratory complex.
Reduced pretomanid exposures.
Avoid coadministration with strong or moderate CYP3A inducers.
Source: G&G 14e · p1277
Drug interaction classified as: metabolism
Source: DDInter
Drug interaction classified as: metabolism
Source: DDInter
Drug interaction classified as: metabolism
Source: DDInter
Drug interaction classified as: metabolism
Source: DDInter
Clinical effect not specified
Source: DDInter
Clinical effect not specified
Source: DDInter
Clinical effect not specified
Source: DDInter
Clinical effect not specified
Source: DDInter
Drug interaction classified as: metabolism
Source: DDInter
Clinical effect not specified
Source: DDInter
Clinical effect not specified
Source: DDInter
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Harrison 22e·Verified: 2026-05-10 · House clinical team